marketing agreement

Under the agreement, the companies plan to make Swift's library preparation kits compatible with MGI's DNBSEQ sequencers.

The companies said the commercial partnership will help increase access to genomic information in the community oncology setting.

The seven-gene test, ColonSentry, is designed to determine an individual's current risk for colorectal cancer relative to an average risk population.

The partners will integrate medical information into LunaDNA pulled from electronic health records via Medfusion's application program interfaces.

The test combines a genetic risk analysis with behavioral and lifestyle assessments, and uses  Thermo Fisher Scientific's TaqMan OpenArray for genotyping.

Oncore and its partners will commercialize GeneNews' ColonSentry test in all countries outside the US and Canada under the five-year exclusive agreement

The partners inked a licensing deal to market and distribute TGen's DeepChek-TB as a compact, portable, and affordable diagnostic model for physician use.

Guardant's lab will make Guardant360 available to doctors and their patients in the region to help identify patients eligible for molecularly targeted drugs.

The deal covers AccuRef's portfolio of CRISPR-engineered cell line-based cancer reference materials for low-to-mid plex clinical genomic applications.

The test can detect over 1,000 pathogens — including bacteria, DNA viruses, fungi, mold, and protozoa — from microbial cell-free DNA in a single blood draw.